Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Source filing unavailable
| Metric | Q3 2011 | Q3 2010 |
|---|---|---|
| Revenue | $1.16M | $815.28K |
| Net Income | -$3.74M | -$4.67M |
| EPS Diluted | -$0.08 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
